Kiran Mazumdar Shaw, Executive Chairperson at Biocon said products such as Yesafili (aflibercept) and Kirsty (insulin aspart) ...

Biocon expects momentum to strengthen in H2FY27, driven by new US biosimilar and generic launches, improved operating ...

Yesafili, an interchangeable biosimilar to Eylea 2 mg, is now commercially available in the United States, according to a ...

Net Sales at Rs 4,336.00 crore in June 2026 up 10% from Rs. 3,941.90 crore in June 2025. Quarterly Net Profit at Rs. 141.10 ...

Net loss of Natural Biocon (India) reported to Rs 0.01 crore in the quarter ended June 2026 as against net profit of Rs 0.14 crore during the previous quarter ...

Biocon also reported a 23% year-on-year decline in interest costs to ₹213 crore after measures to strengthen its balance ...

With the stock currently trading at Rs 435.45, Biocon continues to be an active player in the Nifty Midcap 150 index.

Biocon anticipates a strong second half of FY27 due to US biosimilar launches and favorable regulatory changes enhancing ...

The net profit of Biocon remained at Rs 145 crore for Q1 FY27, but it also included exceptional items or one-time or unusual ...

The company, which is among the world’s top biosimilars manufacturers, remains in a wait-and-watch mode, while exploring ...

Biocon Ltd reported a more than four-fold jump in consolidated net profit for the first quarter of FY27, aided by strong ...